48.02
  Price4.07%   +2.06
 
May-13-22 11:52AM Why Editas Medicine's Shares Fell 28.9% This WeekThe Motley Fool
May-09-22 08:47AM 10 Biggest Price Target Changes For MondayBenzinga
May-06-22 03:02AM Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues BeatZacks Investment Research
May-05-22 08:55AM Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
08:43AM The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder StudyBenzinga
May-04-22 03:19AM Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & MoreZacks Investment Research
May-02-22 07:30AM Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering ConferenceGlobeNewswire Inc.
Apr-28-22 10:09AM Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022Benzinga
09:15AM 4 Analysts Have This to Say About Intellia TherapeuticsBenzinga
Apr-28-22 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company UpdatesGlobeNewswire Inc.
Apr-20-22 07:40AM 3 Top Biotech Stocks Ready for a Bull RunThe Motley Fool
Apr-19-22 06:20AM 3 Ominous Reasons to Avoid This Biotech PioneerThe Motley Fool
Apr-13-22 10:45AM CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030The Motley Fool
Apr-11-22 10:12AM Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?Zacks Investment Research
Mar-17-22 09:36AM Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock?Zacks Investment Research
Mar-16-22 12:27PM Who Benefits From Amazon's Stock Split?The Motley Fool
Mar-11-22 12:23PM Intellia (NTLA) Depreciates 27% Over a Month: Here's WhyZacks Investment Research
Mar-10-22 10:11AM Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AMLZacks Investment Research
Mar-09-22 04:01AM Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia GlobeNewswire Inc.
Mar-07-22 10:03AM Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022Benzinga
Mar-03-22 01:21AM This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch
06:29AM Is Intellia a Good Gene-Editing Stock to Buy Now?The Motley Fool
Mar-03-22 06:15AM Can Biotech Stocks Provide Crypto-Like Growth for Your Portfolio?The Motley Fool
Mar-02-22 07:24AM This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch
Mar-01-22 11:05AM Analyst Ratings For Intellia TherapeuticsBenzinga
07:51AM The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent ResolutionBenzinga
Mar-01-22 07:30AM Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid LeukemiaGlobeNewswire Inc.
06:49AM This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch
Feb-28-22 04:01AM Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinGlobeNewswire Inc.
02:56AM This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch
Feb-28-22 10:09AM This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch
Feb-25-22 09:45AM Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/YZacks Investment Research
Feb-24-22 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company ProgressGlobeNewswire Inc.
Feb-21-22 06:20AM Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?Zacks Investment Research
Feb-18-22 10:06AM Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022Benzinga
Feb-17-22 03:14AM How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months?Benzinga
03:02AM Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to DeclineZacks Investment Research
Feb-17-22 07:30AM Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022GlobeNewswire Inc.
Feb-16-22 11:50AM Intellia (NTLA) Up on Deal With ONK for Cancer TherapiesZacks Investment Research
10:35AM Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?Zacks Investment Research
Feb-15-22 07:30AM Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with CancerGlobeNewswire Inc.
Feb-14-22 10:27AM Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022Benzinga
Feb-03-22 07:30AM Intellia Therapeutics Announces Acquisition of Rewrite TherapeuticsGlobeNewswire Inc.
Jan-29-22 04:25AM A Deep Dive Into the Video Game IndustryThe Motley Fool
10:30AM 3 Growth ETFs to Consider Buying During This CorrectionThe Motley Fool
Jan-22-22 12:35PM Q&A With ARK Invest's Cathie WoodSeeking Alpha
Jan-19-22 10:46AM Editas (EDIT) Focuses on Developing Gene-Editing Eye DrugZacks Investment Research
06:03AM 5 Charts to Remember if the Stock Market Crashes in 2022The Motley Fool
Jan-16-22 06:47AM Is Beam Therapeutics a Good Stock to Buy Now?The Motley Fool
Jan-07-22 02:00AM "Motley Fool Money" 2022 Investing PreviewThe Motley Fool
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):